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Cured yesterday of my disease,
I died today of my Physician.
Thus said Matthew Prior, writing 300
years ago, and the aphorism is
timeless. What has changed is the
public cost of staying the Grim
Reaper’s hand that extra day.
Stephen Hall’s story concerns the
immunotherapy of cancer, and a
mesmerising read it is. His dramatis
personae range from the wholly
admirable to quite a number who
one would not wish to meet in an
alley on a dark night.
The narrative begins with the
New York cancer surgeon, William
Coley. This single-minded loner
observed, around the turn of the
century, that patients in the terminal
stages of some cancers who were
visited by erysipelas infections
seemed on occasion to make
unaccountable recoveries. Pursuing
this lead with fanatical fervour, Coley
eventually developed a bacterial
toxin preparation, which, if it did not
kill, sometimes seemingly cured. As
he became more messianic in
promoting his treatment, so the
hostility of the medical
establishment grew and after his
death no one was willing to carry the
torch. Coley, as we now know, had
hit on adjuvant therapy, which
almost certainly worked, at least for
some sarcomas.
The rise of cellular immunology
brought with it renewed interests in
the prospects for immunotherapy.
With the arrival of the interferons, an
ominous interest stirred in the
boardrooms of the pharmaceutical
companies and, as more and more
cytokines came to light, a frenzy of
activity arose in all branches of the
cancer business. And cancer, as Albert
Szent-Györgyi famously observed,
was already coming close to keeping
more people alive than it killed.
When Carswell and Old isolated
tumour necrosis factor and observed
its startling effect on sarcomas in mice
they worked for several years more
before publishing their results.
That was in 1975 and few of those
who followed showed such
scrupulous restraint. A new breed of
clinical researchers had emerged,
more concerned to get the latest
factor into a hapless patient —
usually with appalling side-effects —
and claim a first than to establish by
painstaking trials whether it actually
did some good. An important part of
research in this area consisted (and
still does) of manipulating the
committees that stand in the way of
heroic experimentation on the sick.
The technique is commonly to
denounce these who weigh the
arguments while patients are dying.
Equally important in committee is to
get a thumb in the eye of a rival. One
of the players in this game put the
matter to Stephen Hall with self-
revealing candour: “The only way to
get there first is to make sure nobody
else gets there first.”
When yet another dramatic claim
was heralded in Time, a leading
molecular biologist, invited to
comment, opined that it was as well
the protagonists had given their press
conference without waiting for the
outcome of the experiment, for
otherwise there would have been
nothing left to report. Gene therapy,
into which cancer immunotherapy
has partly merged, has been no more
successful and no less ferociously
puffed. The eruption onto the scene
of the biotechnology industry has
compounded the mischief, for
neither the companies nor their
backers are generally reconciled to a
five-year wait to determine whether
extravagant claims are matched by
survival statistics: months is more
the time-scale on which the profit
motive operates. A rapacious
industry, a voracious press and a
raging desire for share options and
more especially for that handshake
with the King of Sweden make an
explosively rich mixture.
Concluding his chapter on
interferon, Hall reflects that “… from
a Dickensian point of view, the story
of interferon has evolved into a
fascinating tale of biological paupers
and princes, of graduate students who
became millionaires and visionaries
who did not.” Honourable members
of this last group were Jean
Lindemann, who with Alick Isaacs
discovered interferon in the first
place, and Kari Cantell, who played
such an indispensable part in
purifying α-interferon and producing
it on an unheard-of scale and made it
and his skills available to all comers.
Asked why he had received no reward
from those who are now selling the
stuff to the tune of $500 million
annually, he replied “They did not
offer, and I did not ask.” There is
surely here a conflict of cultures.
A drug in more innocent days
used to be defined as a substance
that, when injected into an animal or
a patient, produces a paper. Now it
has not earned the name if it does
not rather produce $10 billion. One
of Stephen Hall’s informants asked a
pharmaceutical rep why the
recommended dosage for an
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interferon preparation was thrice
weekly. “Because,” came the reply,
“that’s what our marketing
department decided would be best.”
Like another remarkable book
about blood, published 20 years ago,
Richard Titmuss’s The Gift
Relationship, the tale that Stephen
Hall unfolds with such vivid
command is that of our society in
microcosm. Taxes may be
inescapable, but death is
discretionary, its conquest the last
scientific frontier. But it was, I think,
an economist of Titmuss’s generation
who urged that, as in earlier days, the
proper end of life was to collapse
under a huge burden of firewood and
be eaten by wolves.
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Turning points
Evanescent science
Roger Keynes
In his book The Art of the Soluble,
Peter Medawar states that to students
of the 1930s “… experimental
embryology was the subject that
seemed most exciting, … that most
nearly on the threshold of a grand
revelation.” Much of the excitement
was due to the discovery of
embryonic induction by Hans
Spemann and Hilde Mangold, which
promised to reveal not only how
embryos are made but the nature of
molecular instruction itself. The task
proved hard, however, and Medawar
opted for immunology — brilliantly
as it turned out — complaining that
despite the exactitude (“even
punctilio”) of descriptive embryology,
it wouldn’t get far without genetics
and a theory to account for it.
If revelations are the point of
science, the more recent unravelling
of the molecular genetic mechanisms
that pattern fruit fly development
must rank high in grandeur. By the
early 1980s, when I had been
working on regeneration in the
vertebrate nervous system,
development was becoming
increasingly fascinating and the time
seemed ripe for looking at large-
scale, segmental (metameric)
patterning in vertebrate embryos.
Just the kind of thing, you might
think, that would have been sorted
out years ago by biologists and their
light microscopes, but a chance
encounter in the departmental
library with a 1933 paper by George
Streeter [1] entirely changed my
preconceptions.
He had called it “The status of
metamerism in the central nervous
system of chick embryos,” and the
fact that there was any question
about metamerism in vertebrate
embryos was remarkable enough. As
I read on, it was easy to see that here
was an eloquent attempt at the last
word on a subject that had exercised
the nervous systems of previous
generations to the point of passion.
The paper was essentially a
demolition job, and not the first in the
field. In 1858, T.H. Huxley famously
shattered Goethe’s segmented
vertebrate skull, but within 40 years
segmentation had been resurrected
with full force by comparative
embryologists, this time to include
the central nervous system (CNS).
The chief object of Streeter’s
contempt was Charles Hill, who
“… apparently intoxicated by the
simplification of the mechanics of
development that seemed to be
offered by the principle of
metamerism” had the temerity to
suggest that the vertebrate CNS is
metameric in origin “from stem to
stern.” Hill’s drawings, Streeter
cynically declared, illustrated neural
segmentation “… with great daring,”
his “evanescent segments” had been
far too influential, and that to draw
“rigid geometrical” lines across the
developing brain where they did not
exist was nothing short of “an act of
rank pedagogic violence.” Instead,
Streeter insisted simply, neural
segments “… are not justified by the
available evidence” — which
included his own detailed
observations — and that to
pronounce otherwise was “to lean
more toward the principles of the
tailor shop than toward those typical
of living embryonic tissue.” He did
somewhat grudgingly admit that his
anti-metamerism should perhaps be
qualified in the case of the hindbrain
— to me so impressively segmented
from even a glance down the
microscope at a living chick embryo
— but in his main conclusion he took
the extreme view.
To someone schooled in the
unshakeable certainties of
anatomical description, in the belief
that the punctilio of vertebrate
development had been worked over
with such accuracy that all dissent
had been extinguished, this was
heady stuff. Here, it seemed, was the
reason why the field had remained
essentially inactive for the next 50
years, as if dealt a mortal blow by
Streeter’s paper. But at least the
whole business of segmentation in
the nervous system had mattered
once and could therefore matter once
more, and so I was motivated. It was
plain that there was plenty left to do,
that the striking segmental patterns
so visible in the nervous system of
living chicks were more than dead
ducks and should be looked at again.
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